ALGN

TentativeAI Memo

Align

As of 2026-09-29/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Scanner placements versus scanner revenue • 2026-12-31

Base target: $160 / p=45% prob

Biggest risk

Systems and Services revenue fell 10.8% year over year in Q2. Lower scanner prices, flexible acquisition models, softer Q3 revenue guidance, and UK VAT costs could constrain reported growth or margins. [#SEC-8K-2026-07-29] SEC earnings exhibit

Invalidation

Break below $105 or thesis failure.

What would change my mind?

Q2 Clear Aligner revenue grew 8.2% and case volume grew 7.4% year over year. Sustained case growth, scanner placements feeding future treatments, and margin expansion could support a rerating. [#SEC-8K-2026-07-29] SEC earnings exhibit

Research note

Recommendation

—

Confidence

medium

As of

2026-09-29

Base target

$160

p=45%

Bull target

$190

p=25%

Bear target

$105

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 revenue and aligner-volume test
2027 margin-improvement target
Q2 Clear Aligner revenue grew 8.2% and case volume grew 7.4% year over year.

BearKey bullets

Q3 guidance anticipates lower sequential revenue and Clear Aligner selling prices; foreign exchange, demand and restructuring charges add execution risk.
[#SEC-8K-2026-07-29]
Scanner mix: Q2 Systems and Services revenue declined 10.8% year over year; management expects a further 6%–8% full-year decline.

WatchKey bullets

Scanner placements versus scanner revenue

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $160 (p=45%)

Target spread vs base: +19% / -34%

Scenario probabilities

Bull Target: $190 (p=25%)Base Target: $160 (p=45%)Bear Target: $105 (p=30%)

Commentary

News is mixed: company-reported aligner growth contrasts with scanner weakness and softer near-term guidance. A secondary September article reports a post-earnings share decline, but the packet does not establish a verified immediate reaction, consensus surprise, or subsequent analyst revisions. The August 31 board-election filing is not an operating catalyst. [#8-K-2026-08-31] Sentiment fields shown as zero are unavailable observations, not neutral readings; social coverage is insufficient.

As of 2026-09-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 revenue and aligner-volume test
2027 margin-improvement target

Scenarios

Bull Target (Scenario probability)

$190 / p=25% prob

Base Target (Scenario probability)

$160 / p=45% prob

Bear Target (Scenario probability)

$105 / p=30% prob

Analysis 2026-09-29 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Scanner placements versus scanner revenue
Management expects double-digit 2026 iTero shipment growth but a 6%–8% decline in Systems and Services revenue as lower-priced scanners and leasing or rental models change the mix. Evidence that placements subsequently support Invisalign case growth would strengthen the platform thesis; continued revenue erosion would weaken it. [#SEC-8K-2026-07-29] SEC earnings exhibit
Prob 55.00% • Move 9.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Q3 revenue and aligner-volume test
2026-10-31
Align guided to Q3 revenue of $1.00–$1.02 billion, mid-single-digit year-over-year Clear Aligner volume growth, and approximately 24% non-GAAP operating margin. Results will test whether aligner growth offsets weaker scanner economics. The reporting date is unconfirmed; the date below is a monitoring estimate. [#SEC-8K-2026-07-29] SEC earnings exhibit
Prob 60% • Move 8% • Priced-in 45%

Long-term Catalysts

Months to a year

2027 margin-improvement target
2027-12-31
Management preliminarily targeted at least approximately 100 basis points of further GAAP and non-GAAP operating-margin improvement in 2027, but explicitly said this was not formal guidance. A later strategic-review update and delivery against that target would be more meaningful than the aspiration alone. [#SEC-8K-2026-07-29] SEC earnings exhibit
Prob 50% • Move 12% • Priced-in 30%

Risks

Q3 guidance anticipates lower sequential revenue and Clear Aligner selling prices; foreign exchange, demand and restructuring charges add execution risk. [#SEC-8K-2026-07-29]
Scanner mix: Q2 Systems and Services revenue declined 10.8% year over year; management expects a further 6%–8% full-year decline. [#SEC-8K-2026-07-29]
The UK VAT ruling led to an estimated $37.5 million liability, with the appeal outcome uncertain; applicable invoices began including 20% VAT in September. [#SEC-8K-2026-07-29] SEC earnings exhibit

Peers

Symbol	Summary
NVST	Direct dental-device and digital-orthodontics comparator: Envista sells Spark clear aligners and dental imaging products, overlapping with Invisalign and iTero. Compare aligner adoption and dental-workflow trends rather than companywide valuation multiples, because Envista also sells implants and other dental products. Envista businesses
XRAY	Direct dental-device comparator: Dentsply Sirona links SureSmile clear aligners with its Primescan intraoral scanner, providing a closer treatment-and-scanning workflow comparison than diversified medtech names. Its broader dental portfolio still limits whole-company margin and valuation comparisons. Dentsply Sirona SureSmile workflow

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-29

Loading AI feed…

Symbol

Summary

NVST

Direct dental-device and digital-orthodontics comparator: Envista sells Spark clear aligners and dental imaging products, overlapping with Invisalign and iTero. Compare aligner adoption and dental-workflow trends rather than companywide valuation multiples, because Envista also sells implants and other dental products. Envista businesses

XRAY

Direct dental-device comparator: Dentsply Sirona links SureSmile clear aligners with its Primescan intraoral scanner, providing a closer treatment-and-scanning workflow comparison than diversified medtech names. Its broader dental portfolio still limits whole-company margin and valuation comparisons. Dentsply Sirona SureSmile workflow